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Abstract
Background: Meta-analysis is a popular methodology in several fields of medical research, including genetic
association studies. However, the methods used for meta-analysis of association studies that report haplotypes
have not been studied in detail. In this work, methods for performing meta-analysis of haplotype association
studies are summarized, compared and presented in a unified framework along with an empirical evaluation of the
literature.
Results: We present multivariate methods that use summary-based data as well as methods that use binary and
count data in a generalized linear mixed model framework (logistic regression, multinomial regression and Poisson
regression). The methods presented here avoid the inflation of the type I error rate that could be the result of the
traditional approach of comparing a haplotype against the remaining ones, whereas, they can be fitted using
standard software. Moreover, formal global tests are presented for assessing the statistical significance of the overall
association. Although the methods presented here assume that the haplotypes are directly observed, they can be
easily extended to allow for such an uncertainty by weighting the haplotypes by their probability.
Conclusions: An empirical evaluation of the published literature and a comparison against the meta-analyses that
use single nucleotide polymorphisms, suggests that the studies reporting meta-analysis of haplotypes contain
approximately half of the included studies and produce significant results twice more often. We show that this
excess of statistically significant results, stems from the sub-optimal method of analysis used and, in approximately
half of the cases, the statistical significance is refuted if the data are properly re-analyzed. Illustrative examples of
code are given in Stata and it is anticipated that the methods developed in this work will be widely applied in the
meta-analysis of haplotype association studies.
Background
The continuously increasing number of published gene-
disease association studies made imperative the need of
collecting and synthesizing the available data [1,2]. The
statistical procedure with which data from multiple stu-
dies are synthesized is known as meta-analysis [3-5]. In
meta-analysis, a set of original studies is synthesized and
the potential heterogeneity is explored using formal sta-
tistical methods [3,4,6,7]. In the medical literature,
meta-analysis was initially applied in the field of rando-
mized clinical trials [8,9], but nowadays it is considered
av a l u a b l et o o lf o rt h ec o m b i n a t i o no fo b s e r v a t i o n a l
studies [10], as well as for genetic association studies for
which specialized methodology has been developed
[5,11-18].
Most of the genetic association studies (and hence the
meta-analyses derived from them) are performed using
single markers, usually Single Nucleotide Polymorph-
isms (SNPs). However, the SNP that is under investiga-
tion is not always the true susceptibility allele. Instead, it
may be a polymorphism which is in Linkage Disequili-
brium (LD) with the unknown disease-causing locus
[19]. In such cases, the single marker tests may be
underpowered, depending on the degree of LD and the
allele frequencies [20]. Haplotypes, which are the combi-
nation of closely linked alleles on a chromosome, are
therefore important in the study of the genetic basis of
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any medium, provided the original work is properly cited.diseases and thus, they are extensively used [21,22]. The
importance of studying haplotypes ranges from elucidat-
ing the exact biological role played by neighbouring
amino-acids on the protein structure, to providing infor-
mation about ancient ancestral chromosome segments
that harbour alleles influencing human traits [23]. More-
over, haplotype association methods are considered to
be more powerful compared to single marker analyses
[24,25], even though this is questioned by some
researchers [26].
A major problem in haplotype analyses is that in order
for the analysis to be performed we need to reconstruct
or infer the haplotypes, usually with an approach based
on missing data imputation [27-29]. This uncertainty in
imputing the haplotypes poses some problems in the
analysis [30] that are to be discussed later in this work.
Nevertheless, studies that investigate the association of
haplotypes with diseases are increasingly being pub-
lished (Figure 1), with an even more increasing rate
after 2003, when the HapMap project was initiated [31].
This exponential increase follows the general pattern of
gene-disease association studies [1,2,32] and naturally,
the obvious extension would be to use meta-analysis in
order to increase the power of individual studies and to
resolve the reasons of heterogeneity and inconsistency.
This work has two primary goals. First, to perform a
detailed literature search and an empirical evaluation of
the published studies that report meta-analyses of haplo-
type associations; and second, to present a concise over-
view of the statistical methods that could and should be
used in such meta-analyses. These two important issues
were not previously studied in the literature and the
findings are interesting. Even though the methods pre-
sented in this work could be derived in a straightfor-
ward manner from extending previous works on
multivariate meta-analysis [33-37], the majority of the
published meta-analyses did not use optimal methods
for analyzing the data. Moreover, in several circum-
stances the results of some studies are shown to be
severely flawed. The manuscript is organized as follows:
Initially, the commonly used methods for haplotype ana-
lysis for a single study are reviewed in order to establish
notation. Afterwards, the methods of meta-analysis are
presented. In particular, we present the standard method
of univariate meta-analysis and its limitations, which
leads to a more powerful multivariate approach based
on summary-data. Accordingly, a general framework
based on generalized linear mixed models (GLMMs) is
presented and the approaches based on logistic regres-
sion, multinomial logistic regression and Poisson regres-
sion are discussed. We also dis c u s sc o n t i n u o u st r a i t s
and details of the implementation of the models. Finally,
we present the results of the empirical evaluation of the
literature and compare the results reported in these ana-
lyses with the ones obtained using the methods devel-
oped here.
Methods
Methods for haplotype association
Let’sa s s u m ew eh a v en biallelic markers that form a
haplotype. If the alleles in position m (m =1 ,2 . . .n)a r e
denoted by A
m and B
m the possible haplotypes would be
r =2
n. In a case-control study, a cross-tabulation of
haplotypes by disease status, that ignores the individuals
and counts only the total number of haplotypes
observed in the analysis, would result in data arranged
in the form of a 2 × r contingency table (Table 1). This
cross-tabulation is somehow simplistic since it assumes
a multiplicative (co-dominant) model of inheritance
[38]. However, it is the most commonly reported form
of haplotype data and thus, it is more suitable for meta-
analysis of published studies as we will discuss later.
Assuming a binomial sampling scheme where fixed
numbers of cases and controls are sampled indepen-
dently, we can model the structure of the table using
logistic regression methods where the status (case/
Figure 1 A graphical representation of the increasing number
of published haplotype-association studies. A search was
performed in Pubmed using the terms “haplotype” and “association”
from 1997 to 2009. Even though the reference list may include
review articles, methodological papers or even irrelevant works, the
trend is obvious, especially after 2003 when the HapMap project
was presented. The search was conducted during December 2009
and thus the count for 2009 may be an underestimate.
Table 1 Cross-tabulation of haplotypes by disease status
Haplotype (zj) Cases (y = 1) Controls (y =0 )
1 89 183
21 4 2 6
32 4 2 2
43 3
The haplotype data obtained in a case-control study on 182 caucasian women
concerning the association of p53 haplotypes with breast cancer [108]. The
data are presented in the form described by Wallenstein and coworkers [38].
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are treated as covariates. This corresponds to the so-
called “prospective likelihood”, the likelihood based on
t h ep r o b a b i l i t yo ft h ed i s e a s eg i v e nt h ee x p o s u r e .T h u s ,
we denote by πj = P(yj = 1) the underlying risk (i.e. the
probability of being a case) of a person carrying a single
copy of the j
th haplotype. A reasonable choice would be
to consider the most common haplotype (i.e. h1)a st h e
reference category and create r-1 dummy variables tak-
ing values zj = 1 for haplotype j and 0 otherwise. This
model can be formulated as:
logit logit   jj j j
j
r
Py j z () == () ⎡
⎣
⎤
⎦ =+
= ∑ 1 0
2
| (1)
This model was proposed initially by Wallenstein and
co-workers and as we already mentioned, assumes a
multiplicative genetic model of inheritance [38]. More-
over, the haplotypes are assumed known quantities,
which may not always be the case (see below).
Alternatively, assuming a multinomial sampling
scheme where the total sample size is considered fixed,
a multinomial logistic regression model would be appro-
priate, where the different haplotypes would be the
dependent variables. This corresponds to the well-
known “retrospective likelihood” (i.e. the likelihood
based on the probability of exposure given disease sta-
tus) applicable in case control studies. In this case, the
haplotypes are treated as dependent variables and the
case/control status as the predictor in a multinomial
(polytomous or polychotomous) logistic regression [39]:
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By observing that the linear predictor becomes:
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it is easy to understand that the bj coefficients
obtained by fitting the model are estimates of the log-
Odds Ratios (i.e. for comparing hj vs. h1) in equivalence
to the respective coefficients of the model in Eq. (1).
Obviously, b1 = 0 for identifiability since haplotype j =1
(i.e. h1) is used as the reference category. The particular
model was first used for haplotype analysis by Chen and
Kao [40].
Lastly, assuming that the observed counts are realiza-
tions of a Poisson random variable, one can fit log-linear
models (Poisson regression), where the dependent
variable is the counts and thus, the studies, the type of
haplotypes and the case/control status are treated as inde-
pendent variables. Log-linear models are widely used for
haplotype analysis, for instance, for detecting LD [41,42]
and for haplotype-disease association [43,44]. This model
can be formulated in terms of a Poisson regression model
in the context of generalized linear models, as:
log ny a z z y jj j j
j
r
jjj
j
r
() =+ + +
== ∑∑   00
22
(4)
This is the standard saturated model for describing
the 2 × r contingency table of haplotypes by disease.
The bj’s are the coefficients that correspond to the hap-
lotype by disease interaction and are equivalent to those
obtained by fitting the models in Eq. (1) and (2). It is
easily verified that the coefficients a’s and b’s are identi-
cal across the three models. The overall hypothesis for
association (b = 0) can be tested by performing a multi-
variate Wald test using the estimated covariance matrix,
cov(b). Then, the test statistic (score) U = b’cov(b)
-1b,
will have asymptotically a c
2 distribution on r-1 degrees
of freedom. Alternatively, a likelihood ratio test compar-
ing the saturated model against the model with no inter-
action can be performed. Similar tests can be performed
for the models in Eq. (1) and (2).
Whatever the assumed sampling scheme that gave rise
to the data of Table 1 may be, it is well known that the
results of fitting each one of the three models are nearly
identical [45]. For instance, it has been shown that max-
imum likelihood estimates obtained from the “retrospec-
tive” likelihood are the same as those obtained from the
“prospective” likelihood [46,47]. The equivalence of
logistic regression and Poisson modelling has been also
exploited in the past for deriving methods for detecting
gene-environment interactions [48].
The methods discussed above are simple applications
of the generalized linear model extending the analysis of
single markers to haplotypes and assume that, i) the
haplotype risk follows a multiplicative model of inheri-
tance, ii), the haplotype phase is known and, iii) the
population is in Hardy-Weinberg Equilibrium (HWE).
The genetic model of inheritance can be handled simply
by using in the analysis the so-called haplo-genotypes or
diplotypes, instead of the genotypes. This is easily per-
formed with all the previously presented methods by
using the pairwise combinations of haplotypes (h1h1,
h1h2 and so on). In case-control association studies,
however, with the exception of some cases where direct
genotyping of the haplotypes is applicable (i.e. [38]), the
haplotypes (and the haplo-genotypes) are usually not
known, but are inferred from the data using statistical
methods for missing data, usually with an EM or EM-
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quantities has been shown to be problematic [30]. More
advanced methods have been developed in order to
account for these limitations, for instance weighting the
haplotypes by their probability [49,50]. Score methods
based on the prospective likelihood [51] or the retro-
spective likelihood [52], have also been developed, as
well as methods for allowing for gene-environment
interaction [53]. A comparison of methods has shown
that the approaches are roughly comparable when the
haplotype effect on disease odds follows a multiplicative
model. However, for dominant and recessive models,
the retrospective-likelihood method has increased effi-
ciency with respect to the prospective methods [54].
Graphical models have been proposed by Thomas [55]
and log-linear models by Baker [56]. Lin and co-workers
extended the previously presented methods by including
various sampling schemes in a unified framework [57].
Even though a large body of the genetic epidemiology
literature is dedicated to such methods, their application
in meta-analysis is problematic since in most cases the
original data are not available to the analyst. Thus, in
the following sections where the methods for meta-
analysis are summarized we also assume that the
haplotypes are known. An extension when the posterior
probabilities of haplotypes are given from the output of
t h eh a p l o t y p ei n f e r e n c es o f t w a r ew o u l dt h e nb e
straightforward.
Methods for meta-analysis of haplotype association
In this section the methods for meta-analysis are pre-
sented. Initially we will discuss simple methods using
summary data, whereas in the next sub-section more
advanced methods that use generalized linear models on
grouped or Individual Patients Data (IPD) are presented.
Meta-analysis using summary-data
A commonly used approach that is based on traditional
methods and uses solely summary data is to consider
separately the effect of the j
th haplotype against the j-1
remaining ones. That is, for each study i (i = 1,2,...,k)w e
will compute a log-Odds Ratio (logOR):
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with an asymptotic variance given by:
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In this notation, nic0 an nic1,a r et h ec o u n t so ft h e
remaining haplotypes (excluding haplotype j)f o r
controls and cases of the i
th study respectively, given
by:
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In a standard univariate random-effects model we
assume that the logarithm of the OR of each study i,i s
distributed normally as:
yN s ii −+ ()  ,
22 (8)
Thus, the combined logarithm of the Odds Ratio
(logOR) would be given by:
 
∧
== + ()
== ∑∑ ww w s ii i
k
i i
k
ii 11
22 1 , with  (9)
The between-studies variance (τ
2), could be easily
computed by the non-iterative method of moments pro-
posed by Dersimonian and Laird [58], even though
there are several alternatives that use iterative proce-
dures (i.e. Maximum Likelihood (ML) or Restricted
Maximum Likelihood (REML) [33]). Apparently, by set-
ting τ
2 = 0 in Eq. (9) corresponds to the well known
fixed-effects estimator with inverse variance weights.
The particular approach is very easily implemented,
intuitive and it can be performed in a standard univari-
ate meta-analysis framework. In the results section we
will see that several already published meta-analyses
used this method. However, the method has some draw-
backs. The most important is that it is prone to an
increased type I error rate due to multiple comparisons.
Multiple comparisons constitute an important problem
in haplotype analysis, especially as the number of haplo-
types increases [59,60]. The model implied by Eqs. (5) -
(8), is conceptually similar to collapsing the genotypes
in a single-marker analysis, an approach that has been
shown to increase the power as well the type I error
rate [61]. Thus, the particular approach can be justified,
only when there is strong prior knowledge concerning a
particular haplotype and this haplotype is the only one
that is being tested.
To overcome the multiple comparisons problem, a
straightforward alternative would be to extend the
model in a multivariate framework modelling simulta-
neously the logORs derived from comparing haplotypes
j = 2,3,...,r against a reference haplotype (j = 1). Follow-
ing the general framework for multivariate meta-analysis
[ 3 7 , 6 2 ] ,w ed e n o t eb yyi the vector containing the r-1
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means given by:
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These logORs similarly to Eq. (5) will be given by:
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with an asymptotic variance given by:
var ys
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In the multivariate random-effects meta-analysis, we
assume that yi is distributed following a multivariate
normal distribution around the true means b, according
to the marginal model:
yC ii MVN   ,  + () (13)
In the above model, we denote by Ci the within-stu-
dies covariance matrix:
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and by Σ the between-studies covariance matrix, given by:
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The diagonal elements of Ci are the study-specific esti-
mates of the variance that are assumed known, whereas
the off-diagonal elements correspond to the pairwise
within-studies covariances, for instance rw23s2is3i=cov(y2i,
y3i). Since the logORs derived for each haplotype are
compared against the same reference category, their pair-
wise covariances will be given [12], by:
cov , , , ’ , ,... , ’ ’ yy
nn
jj rj j ji j i
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11
23
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We should mention that from standard normal theory it
is known that the multivariate test for b =0 , based on
b’cov(b)
-1b, could yield significant results even if all the r-1
univariate Wald tests are non-significant. Thus, the multi-
variate test should be performed initially and only if a sig-
nificant result is found we can proceed by collapsing the
haplotypes and perform a standard univariate meta-analysis.
The model can be fitted in any statistical package cap-
able of fitting random-effects weighted regression models
with an arbitrary covariance matrix, such as SAS (using
PROC MIXED or PROC NLMIXED), R (using lme) or Stata
(using mvmeta). In this work, we used mvmeta which
performs inferences based on either Maximum Likelihood
(ML) or Restricted Maximum Likelihood (REML), by
direct maximization of the approximate likelihood using a
Newton-Raphson algorithm [63]. Alternatively, mvmeta
can also implement the multivariate version of the DerSi-
monian and Laird’s method of moments [64]. The last
option, being non-iterative, is very attractive in case of
large number of haplotypes and/or large number of stu-
dies. A major disadvantage of the methods proposed in
this section is the assumptions of normality that are
employed and the need for correction when there are rare
haplotypes (i.e. adding a pseudocount of 0.5 to the haplo-
t y p e sw i t hz e r oc o u n t s ) .T h e se limitations are surpassed
by using the methods discussed in the next section.
Meta-analysis using binary data
In this section, methods that use directly the binary nat-
ure of the data, within a generalized linear mixed model
(GLMM) are presented. These methods are usually
termed IPD methods [33-37] although in many real-life
applications, individual data may not be literally avail-
able. Instead, extending the models described for a sin-
gle study, only summary counts of individuals carrying
the respective haplotypes will normally be used.
Logistic regression
Using the prospective likelihood we can extend the logis-
tic regression model of Eq. (1) in order to incorporate
study specific effects and perform a stratified analysis
(fixed effects meta-analysis). To do so, we need to intro-
duce k-1 dummy variables di (taking values equal to zero
or one) with coefficients b0i that are indicators of the
study-specific fixed-effects. Thus, the model is a straight-
forward extension to the model described previously for
meta-analysis of genetic association studies for single
nucleotide polymorphisms [16] and is formulated as:
logit logit
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overall estimates of the logORs (i.e. for comparing hj vs.
h1). An overall test for the association of haplotypes
with disease can be performed if we denote by b the
vector of the estimated coefficients and by cov(b) its
estimated variance-covariance matrix. Then, the test sta-
tistic U = b’cov(b)
-1b will have asymptotically a c
2 dis-
tribution (U~c
2
r-1) [65]. The particular model has been
used in several meta-analyses of haplotype association
studies [66-69] (see in the results section, the empirical
evaluation of the literature). This fixed effects model
assumes homogeneity of ORs between studies. This
assumption can be tested by adding the interaction
between the study effect and the haplotypes into the
model::
logit logit
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This is the analogue to the Cochran’st e s tf o rh e t e r o -
geneity in the univariate meta-analysis. The hypothesis
can be tested by performing a multivariate Wald test,
where the null hypothesis is:
Hi k j r ij 0 02 3 2 3 : , , ,..., ; , ,...,   == ∀ = = () 0  
The test statistic can be constructed analogously to
the one used for b.I fw ed e n o t eb yg the vector of the
estimated coefficients, by V the estimated variance-cov-
ariance matrix and by Rg =rthe vector of the (r-1)(k-1)
linear hypotheses, then the statistic:
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will have asymptotically a c
2 distribution [65]
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Moreover, the value of W could be used in order to
calculate a modified version of the overall inconsistency
index I
2 [70]:
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This measure is quite useful, since it enables us to
summarize the overall heterogeneity, instead of having
to look at multiple indices of heterogeneity arising from
multiple haplotype contrasts.
In order to account for an additive component of het-
erogeneity and perform a random-effects logistic regres-
sion allowing the haplotype effects to vary between
studies, the most suitable way is to introduce a set of
study-specific random coefficients, representing the
deviation of study’s true effect from the overall mean
effect for each haplotype. Thus, the model becomes:
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In this model, the random terms bi are distributed as:
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The between studies variances and covariances have
the same interpretation as the ones obtained by the
summary-data methods of Eq. (13) and (15).
Multinomial logistic regression
Alternatively, the model may be parameterized assuming
a multinomial sampling scheme utilizing the retrospec-
tive likelihood. In this case, an extension of the model
of Eq. (2), which incorporates fixed-study effects, would
be:
pP j y
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The linear predictor in the above model becomes:
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the variables di are indicators of the study-specific fixed-
effects. An overall test for the association of haplotypes
with disease (b =0 ) can be performed similarly to the
logistic regression model (U). Introducing the study by
disease interaction terms can form a test for homogene-
ity of ORs across the k studies:
U
p
p
dy d y ij
ij
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j i ji ji j i jii j
j
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(27)
The statistics for heterogeneity (W)a sw e l la st h eI
2
index derived from it are identical to the one presented
in Eq. (19) - (21).
A random-effects extension to the model can be for-
mulated if in the above model, we introduce a haplo-
type-specific random coefficient bij (for haplotypes j =
2,3, ...,r), in which case the linear predictor becomes
[71]:
U
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(28)
and the model is completely specified as a random
effects multivariate meta-analysis, with random terms bi
distributed similarly as bi~MVN(0,Σ). The interpretation
of the variances and covariances of the random terms is
identical to the ones presented in Eq. (13). A version of
this model has been used previously for meta-analysis of
genetic association studies involving single nucleotide
polymorphisms [12], but according to the author’s
knowledge it has never been used for meta-analysis of
haplotypes.
Poisson regression
Lastly, we can extend the log-linear model of Eq. (4) in
order to perform a fixed effects meta-analysis allowing
for the study-specific effects. The major difference
compared to the previous approaches lies in the struc-
ture of the log-linear model and the interpretation of
the main effects and interactions. Having in mind that
we want to model a 2 × r × k contingency table, the
appropriate choice would be to include in the model
of Eq. (4) the study specific main effects as well as the
t w o - w a yi n t e r a c t i o n s( s t u d yxd i s e a s ea n ds t u d yxh a p -
lotype). Thus, we would have a model containing all
the main effects as well as all the two-way interactions,
a model known as the “no three-factor interaction
model“ [45]:
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In this model, the coefficients aj, aij, b0, b0j and bj
correspond to the ones obtained by fitting the models in
Eq. (17) and Eq. (15). The overall test for the association
of the haplotypes with the disease (b = 0), is known in
the context of log-linear models as the test of “partial
association“ [72,73]. The model in Eq. (29), assumes
homogeneity of ORs across studies. Thus, in order to
test this assumption we need to include additional terms
for the three-way interaction (study x disease x haplo-
type). This is accomplished by fitting the saturated
model:
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The test with the null hypothesis Η0: g =0(gij =0 , i =
2,3,...,k, j = 2,3,...,r) is identical to the ones obtained by
fitting the models in Eq. (18) and (27). The three-way
interaction model and its interpretation in terms of test-
ing the homogeneity of ORs has been discussed in detail
in the past [45,74-76]. Log-linear models have been
employed in several meta-analyses of haplotype associa-
tion [77,78] (see in the results section). However, even
though not described in detail, it is apparent from the
results reported, that in these analyses the log-linear
model was not applied in an appropriate manner.
Although the authors stated that they performed stratifi-
cation by study, they probably included only the main
effect of the study and not the interaction terms with
both haplotypes and disease. As we will see in the
results section, when the correct model is applied, the
originally drawn conclusions are compromised.
In analogy to models in Eq. (22) and (28), a random
coefficient for the disease by haplotype interaction can
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analysis:
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with random terms bi distributed similarly as bi~MVN
(0,Σ). Similarly to the multinomial logistic regression
model, the interpretation of the variances and covar-
iances of the random terms is identical to the ones pre-
sented in Eq. (12).
Continuous traits
The methods discussed so far assume we are dealing
with a binary trait, usually in a case-control setting.
However, continuous traits are not uncommon in
genetic association studies and these should be easily
accommodated using a linear model (linear regression).
For instance, denoting by yij the continuous trait for a
person carrying the j
th haplotype in the i
th study, the
model would be:
yd z ij i i j j
j
r
=+ +
= ∑   00
2
(32)
The homogeneity of haplotype effects across studies
can be subsequently checked using a model with a hap-
lotype x study interaction term:
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(33)
Finally, a random effects model could be formulated
using a liner mixed model:
yd z ij i i j ji j
j
r
=+ + + ()
= ∑   00
2
(34)
with random terms bi distributed similarly as
bi~MVN(0,Σ). Similarly to the previously described
models, the interpretation of the variances and covar-
iances of the random terms is identical to the ones
presented in Eq. (12). In case where individual data are
not available, the above models could be easily fitted
using summary data (mean values and standard devia-
tions) per haplotype.
Implementation
The models presented in this section can be easily fitted
in Stata using gllamm,o ri nS A Su s i n gPROC
NLMIXED. These models are expected to perform better
compared to the models presented in the previous sec-
tion, in case the normality assumption for logORs does
not hold. Furthermore, a major advantage of these mod-
els is that they can directly be used for pooled meta-
analyses performed under large collaborative projects.
This is why these models are usually termed Individual
Patients Data (IPD) methods [36]. However, a disadvan-
tage is that these methods are computational intensive,
especially when the number of haplotypes is large.
A sometimes useful simplification can be made in Eq.
(15) if we assume that the between-studies variances are
equal [34]. In such case by letting τ = τ2 = τ3 = ... = τr, Σ
reduces to:
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Another approximation would be to impose a single
between studies correlation, but allow for different
between-studies variances [79]:
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In this work however, we chose to use a different
approximation that can be obtained if the number of
random effects is reduced by decomposing the random
terms using factor loadings such as: τ2
2 = l2
2τ
2, τ3
2 =
l3
2τ
2,. . . ,τr
2 = lr
2τ
2,a n dl e t t i n gl2 = 1 for identification.
Thus, the covariance matrix becomes now:
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(37)
The particular approximation is conceptually similar
to the one used previously for the so-called “genetic
model-free approach” for meta-analysis of genetic asso-
ciation studies [14,80], even though the motivation was
different. The model imposes a single between studies
variance τ
2 thus, it is much faster since the factor
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parameters. By observing also the off-diagonal elements
of the covariance matrix in Eq. (37), we can see that the
model restricts the between-studies correlations (rBjj’)t o
be equal to ±1 (depending on the sign of ljlj’). Never-
theless, the between-studies correlations are usually
poorly estimated especially when the number of studies
is small (<20) and in such cases they are usually esti-
mated to be equal to ±1 [81,82]. Thus, the particular
approach seems to be a good compromise between
speed and precision and we expect to perform well.
Using this approach, the computational complexity as
well as the execution time is reduced drastically but the
obtained estimates agree up to the fourth decimal place
in most of the experiments conducted.
A final comment has to be made concerning the iden-
tifiability of the models presented in the previous sec-
tions, especially when it comes to the log-linear models
which are the ones that contain the largest number of
parameters. Concerning the fixed effects methods, the
number of parameters of the saturated model of Eq. (30)
is equal to 2rk, a number that is equal to the number of
observations [45]. For the model of Eq. (29), the number
of freely estimated parameters is equal to rk + r + k-1,
which is obviously smaller than 2rk (since r >1a n dk >
1). The random effects model of Eq. (31) has a total num-
ber of parameters equal to rk + r + k-1 + r(r-1)/2 since
we need to estimate additionally r(r-1)/2 elements of the
covariance matrix (the variances and the covariances of
the random effects). Thus, in order for the model to be
identifiable we need to ensure that rk + r + k-1 + r(r-1)/2
≤ 2rk which is accomplished if k; ≥ 1+r/2. Intuitively, we
need a relatively larger number of studies compared to
the number of haplotypes. If on the other hand, we fit
the model of Eq. (31) using Eq. (35) for restricting the
covariances, we only need rk + r + k parameters and
when we use Eq. (36) or Eq. (37), we need to estimate rk
+2r + k-1 parameters, numbers which both are smaller
than 2rk. Nevertheless, for practical applications, we will
normally use the logistic regression model of Eq. (22)
coupled with parameterization of Eq. (37), and thus iden-
tifiability issues will never arise in practice.
In Additional file 1, Stata programs for fitting the
models developed in this section are presented. The
models were fitted using the gllamm module for Stata
[83,84]. gllamm uses numerical integration by adaptive
quadrature in order to integrate out the latent variables
and obtain the marginal log-likelihood. Afterwards, the
log-likelihood is maximized by Newton-Raphson using
numerical first and second derivatives.
Results
We initially performed a literature search for identifying
studies that report meta-analyses of haplotype
associations. The initial search in PUBMED using the
term “haplotype” combined with “meta-analysis” or “col-
laborative analysis” or “pooled analysis” yielded 282 stu-
dies. Of these, 35 studies could have been identified
using solely the terms “collaborative analysis” or “pooled
analysis” and “haplotype”. After careful screening, 207
studies were excluded as irrelevant ones (they were not
meta-analyses of haplotypes), 36 studies were excluded
for various reasons (family based-studies, meta-analyses
of SNPs with the term “haplotype” appearing in the
abstract or haplotype analyses in which the term “meta-
analysis” appeared in the abstract etc). Finally, we came
up with 39 published papers containing data for 43
associations. Some studies reported different sets of hap-
lotypes from the same gene (Auburn et al, 2008; Zint-
zaras et al, 2009), haplotypes from different genes
(Thakkinstian et al, 2008), or distinct outcomes mea-
sured on different subsets of patients (Kavvoura et al,
2007) and thus, they were included twice, whereas from
studies that reported different outcomes measured on
t h es a m es e to fi n d i v i d u a l sw ek e p to n l yo n e .T h e r e
were also some pairs of studies that evaluated the same
association and from these we kept only the largest one.
10 out of the 39 published papers could have been iden-
tified using solely the terms “collaborative analysis” or
“pooled analysis” coupled with the term “haplotype”.
The 43 studies and their characteristics are presented in
Table 2.
The average number of polymorphisms included in
the haplotypes was 3.19 (SD = 1.37, median = 3, range
from 2 to 7), whereas the sample size was 5,017.81 (SD
= 4,703.24, median = 3,004, range from 348 to 23,309).
The average number of included studies was 5.14 (SD =
3.06, median = 4, range from 2 to 13). Twenty seven
studies (62.79%) were conducted in a collaborative set-
ting, whereas sixteen (37.21%) were performed using
data derived from the literature. Twenty seven of the
meta-analyses (62.79%) reported significant results and
the majority (22 studies, 51.16%) were analysed under
the “1v s .o t h e r s ” approach using standard summary
based meta-analysis techniques (with fixed or random
effects), 11 studies (25.58%)w e r ea n a l y s e db yp o o l i n g
the data inappropriately, 6 studies (13.95%) did not
report the method or did not perform pooling at all and
4 analyses (9.30%) were performed using a fixed effects
logistic regression model. Only 13 studies (30.23%)
reported the complete data that suffice for the analysis
to be replicated (Table 2 and 3).
There was only some weak evidence where collabora-
tive meta-analyses contained larger number of studies
compared to literature-based ones (5.67 vs. 4.25), larger
sample size (5,651 vs. 3,948) and produced significant
results more frequently (66.67% vs. 56.25%). However,
these differences did noreach statistical significance
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Page 9 of 16Table 2 List of the 43 meta-analyses that were used in the empirical evaluation
ID Reference Gene/
Locus
Disease/
Outcome
SNPs in
haplotype
Number of
studies
Sample
Size
Method of
analysis
Data
availability
Collaborative
analysis
Significant
results
1 [109] DRD3 Schizophrenia 4 5 7551 1 vs. others No No No
2 [98] ITGAV Rheumatoid
Arthritis
3 3 6851 N/A Yes Yes Yes
3 [110] IL1A/IL1B/
IL1RN
Osteoarthritis 7 4 2908 1 vs. others No Yes Yes
4 [111] FRZB Osteoarthritis 2 10 12380 1 vs. others No Yes No
5 [99] CX3CR1 CAD 2 6 2912 1 vs. others Yes No Yes
6 [112] ALOX5AP Stroke 4 5 5765 1 vs. others No No No
7 [112] ALOX5AP Stroke 4 3 3004 1 vs. others No No No
8 [113] GNAS Malaria 3 7 8154 1 vs. others No Yes Yes
9 [113] GNAS Malaria 7 6 7632 1 vs. others No Yes Yes
10 [114] PDLIM5 Bipolar
Disorder
2 3 1208 1 vs. others No No No
11 [115] PDE4D Stroke 2 4 4961 1 vs. others No No Yes
12 [116] TGFB1 Renal
Transplantation
2 4 438 pooled No No Yes
13 [116] IL10 Renal
Transplantation
3 4 348 pooled No No No
14 [117] 9p21.3 CAD 4 5 7838 1 vs. others No Yes Yes
15 [118] HLA SLE 2 3 527 1 vs. others No No Yes
16 [94] CTLA4 Graves Disease 2 10 2564 1 vs. others Yes Yes Yes
17 [94] CTLA4 Hashimoto
Thyroiditis
2 5 1210 1 vs. others Yes Yes Yes
18 [119] ENPP1 T2DM 3 3 8676 1 vs. others No No No
19 [77] MTHFR ALL 2 4 894 Log-linear
model
No No Yes
20 [97] CAPN10 T2DM 3 11 5862 1 vs. others Yes Yes Yes
21 [93] ADAM33 Asthma 5 3 1899 pooled Yes No No
22 [120] NRG1 Schizophrenia 6 11 8722 1 vs. others No No Yes
23 [121] RGS4 Schizophrenia 4 8 7243 1 vs. others No Yes No
24 [122] ADRB2 Asthma 2 3 2060 N/A No No Yes
25 [123] ESR1 Fractures 3 8 14622 1 vs. others No Yes Yes
26 [78] VDR Osteoporosis 3 4 2335 Log-linear
model
Yes No Yes
27 [95] ACE Alzheimer’s
Disease
3 4 1619 pooled Yes Yes Yes
28 [124] IGF-I IGF-I levels 3 3 1929 1 vs. others No Yes Yes
29 [125] TF Stroke 2 2 818 N/A No Yes No
30 [92] FcgammaR Celliac Disease 2 2 1057 N/A Yes Yes No
31 [69] VDR Fractures 3 9 23309 Logistic
regression
No Yes No
32 [96] G72/G30 Schizophrenia 2 2 1541 N/A Yes Yes Yes
33 [68] VEGF ALS 3 4 1912 Logistic
regression
Yes Yes Yes
34 [126] BANK1 Rheumatoid
Arthritis
3 4 4445 1 vs. others No Yes Yes
35 [67] CYP19A1 Endometrial
Cancer
2 10 13283 Logistic
regression
No Yes Yes
36 [127] CRP T2DM 3 3 11876 N/A No No Yes
37 [66] 8q24 Colorectal
Adenoma
4 3 5385 Logistic
regression
No Yes Yes
38 [128] CYP1A1 Lung Cancer 2 13 2151 Pooled No Yes Yes
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Page 10 of 16(p-values equal to 0.144, 0.256 and 0.506 respectively).
The average number of included polymorphisms was
also comparable (3.26 vs. 3.06, p-value = 0.654). The
thirteen meta-analyses that reported complete data, did
not differ significantly from the remaining ones in terms
of the included studies (4.46 vs. 5.43, p-value = 0.345),
the number of SNPs in the haplotypes (3.08 vs. 3.23, p-
value = 0.735) and the proportion of significant findings
(69.23% vs. 60%, p-value = 0.576). The proportion of
collaborative analyses was higher, even though this dif-
ference did not reach statistical significance (76.92% vs.
56.57%, p-value = 0.216). There was however, moderate
evidence that the total sample size included in the
meta-analyses that reported complete data was smaller
compared to the meta-analyses that did not (3,040.31 vs.
5,874.73, p-value = 0.069). We also compared the parti-
cular database against a database of 55 representative
meta-analyses of genetic association studies of SNPs
that was used previously in several empirical evaluations
[85-89]. The mean sample size was approximately equal
(5,017 vs. 4,829, p-value = 0.844), but the number of
included studies was nearly halved in the meta-analyses
of haplotypes (5.14 vs. 10.53, p-value < 10
-4), whereas
the proportion of meta-analyses with significant results
was twice as large (62.8% vs. 27.27%, p-value = 0.0003).
The thirteen studies that reported the data necessary
for the analysis to be replicated were subsequently used
in order to apply the methods proposed in this work.
We used all the methods described in the methods sec-
tion except for the simpler approach of comparing 1 vs.
the others haplotypes, i.e. Eq.(5). The results are
reported in Table 3, where we list the p-values for the
tests for the overall association (b = 0). For the fixed
effects IPD methods we additionally report the p-value
of the overall test for the heterogeneity (g =0 ). Con-
cerning the results obtained using the IPD methods, we
report only the ones obtainedf r o mt h el o g i s t i cr e g r e s -
sion method of Eq. (22) using the parameterization of
Eq. (37) which is easier to be fitted, even though the
multinomial logistic regression and the Poisson regres-
sion method would yield similar results. As expected,
when the heterogeneity is low (in 8 out of the 13
studies), the random effects methods coincide with their
fixed effects counterparts. In general, the methods that
use summary data yield slightly different estimates for
the ORs compared to the methods that use IPD, when
there were rare haplotypes (i.e. small counts) or when
the total number of subjects was low (data not shown).
In 2 out of the 13 studies the estimates for the multi-
variate Wald tests for the overall association (b =0 )
produce marginally different results compared to the
univariate ones.
The subsequent re-analysis and the contrasting with
the initial reports yielded some important findings. Con-
cerning the four studies that initially reported no signifi-
cant association [90-93], the methods presented in this
work largely support the initial conclusions. Three of
the nine studies (33.33%) that reported statistically sig-
nificant results [94,95] yielded results that are in com-
plete agreement with the initial reports (the meta-
analysis of Kavvoura and co-workers reported results for
two outcomes and it was counted twice). The most
important finding, however, was the observation that 4
out of the 9 studies (44.44%) [78,96-98], yielded results
that contradict the initial reports. Two additional studies
[68,99] produced marginally significant results as judged
by the disagreement between the multivariate and uni-
variate Wald tests (Table 3).
The reasons for these discrepancies deserve further
investigation. For instance, in the collaborative meta-
analysis for the association of CAPN10 haplotypes with
Type 2 Diabetes mellitus [97], the authors report a mar-
ginally significant OR of 1.09 (1.00, 1.18) for the “1-2-1”
haplotype and similar results for two haplogenotypes
that include this haplotype. Similar results were pre-
viously reported in a literature-based meta-analysis
[100]. However, these estimates have been derived using
the “1v s .o t h e r s ” approach, which although more
powerful, it is known to suffer from increase type I
error rate; thus it seems that these estimates are the
result of a multiple testing procedure. For the meta-
analysis concerning the association of ITGAV haplo-
t y p e sw i t hR h e u m a t o i dA r t h r i t i s[ 9 8 ] ,a sw e l la st h e
association of G30/G72 haplotypes with schizophrenia
Table 2 List of the 43 meta-analyses that were used in the empirical evaluation (Continued)
39 [91] TNFA Prostate Cancer 5 2 4881 Pooled Yes Yes No
40 [90] PTGS2 Prostate Cancer 4 2 4881 Pooled Yes Yes No
41 [129] AR Endometrial
Cancer
5 2 1424 Pooled No Yes No
42 [130] MGMT Head and Neck
Cancer
2 3 1347 Pooled No Yes No
43 [131] SNCA Parkinson
Disease
2 11 5344 1 vs. other No Yes Yes
We list the reference, the gene name, the disease, the number of SNPs included in the haplotypes, the number of studies, the total sample size, the methodo f
analysis (N/A: not available), the availability of data, whether the data was collected in a collaborative setting and whether the study reported significant results.
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of estimates was performed, but the methods presented
in this work suggest clearly that there is not enough evi-
dence supporting the claimed associations. Finally, in
the case of the meta-analysis for the association of VDR
polymorphisms with osteoporosis, in which the authors
claimed to use a log-linear model [78], the initially
drawn conclusions are not supported. It seems that the
authors did not use a correctly specified model that con-
t a i n sa l lt h em a i ne f f e c t sa sw e l la sa l lt h et w o - w a y
interactions (i.e. the “no three-factor interaction model“).
This probably resulted in performing a meta-analysis
essentially without stratifying by study. Given that in the
particular dataset the heterogeneity is large, it is of no
surprise that the originally drawn conclusions are com-
promised after the re-analysis, which strongly indicates
that there is no evidence to support a significant asso-
ciation. Concerning the two datasets for which we
observed disagreement between the multivariate and
univariate Wald tests, i.e. the association of CX3CR1
haplotypes with CAD [99] and the association of VEGF
haplotypes with ALS [68], there were different reasons
for the discrepancies. In the meta-analysis of CX3CR1
haplotypes (which was originally performed using the “1
vs. others” approach) the small discrepancies could be
attributed to the marginal statistical significance (p-
values = 0.06-0.09) and the existence of a rare haplo-
type. In the case of the VEGF meta-analysis, the authors
initially used a fixed-effects logistic regression model
analogous to Eq. (17); however, the moderate heteroge-
neity produced slight discrepancies in the results of the
multivariate Wald test under the random effects model
(Table 3).
Discussion
Although the studies reporting haplotypes comprise a
small fraction of genetic association studies, their num-
b e ri si n c r e a s i n g l yg r o w i n ga n ds ot h e r ei san e e df o r
developing formal methods for combining them in a
meta-analysis. In this work, a comprehensive framework
for the meta-analysis of haplotype association studies
was presented and an empirical evaluation has been per-
formed for the first time in the literature.
The methods proposed in this work are extending pre-
vious works in meta-analysis of genetic association stu-
dies [12,16] in order to handle the multiple haplotypes.
Table 3 The results obtained using the methods described in this work on the 13 studies that reported complete data
that suffice for the analysis to be replicated
ID/
[reference]
Gene/
Locus
Disease/
Outcome
SNPs in
haplotype
Number of
studies
Significant
results
Fixed effects Random effects
b =0
(summary
data)
b =0
(IPD)
g =0
(IPD)
b =0
(summary
data)
b =0
(IPD)
2/[98] ITGAV Rheumatoid
Arthritis
3 3 Yes
$$ 0.2506 0.2489 0.1564 0.3288 0.3851
5/[99] CX3CR1 CAD 2 6 Yes
$ 0.0834* 0.0677* 0.6263 0.0883* 0.1031*
16/[94] CTLA4 Graves
Disease
2 10 Yes <0.0001 <0.0001 0.0371 <0.0001 <0.0001
17/[94] CTLA4 Hashimoto
Thyroiditis
2 5 Yes 0.0011 0.0010 <0.0001 0.0044 0.0072
20/[97] CAPN10 T2DM 3 11 Yes
$$ 0.1152 0.1036 0.6145 0.2243 0.1655
21/[93] ADAM33 Asthma 5 3 No 0.6209 0.5508 0.4697 0.6134 0.5503
26/[78] VDR Osteoporosis 3 4 Yes
$$ 0.1458 0.3051 <0.0001 0.1480 0.5781
27/[95] ACE Alzheimer’s
Disease
3 4 Yes 0.0193 0.0218 0.8906 0.0193 0.0223
30/[92] FcgammaR Celliac
Disease
2 2 No 0.7331 0.7335 0.9502 0.7331 0.7336
32/[96] G72/G30 Schizophrenia 2 2 Yes
$$ 0.7790 0.7757 0.0001 0.5750 0.6719
33/[68] VEGF ALS 3 4 Yes
$ 0.0437* 0.0414 0.0691 0.0716 0.0455*
39/[91] TNFA Prostate
Cancer
5 2 No 0.2531 0.2515 0.6185 0.2867 0.2511
40/[90] PTGS2 Prostate
Cancer
4 2 No 0.3560 0.3550 0.2087 0.6573 0.4829
For either fixed or random effects methods, we list the p-values for the tests for the overall association (b = 0) using the summary data based methods and the
IPD methods. The results for the IPD methods were obtained from the logistic regression method even though the multinomial logistic regression and the
Poisson regression method yield nearly identical results. For the fixed effects IPD methods we also list the p-value of overall test for the heterogeneity (g = 0).
(*): The significance of the multivariate Wald test (b = 0) contradicts univariate one (bj = 0).
(
$): The initially claimed statistically significant results are contradicted by either the multivariate or univariate Wald tests (random effects).
(
$$): The initially claimed statistically significant results are contradicted by both the multivariate and univariate Wald tests (random effects).
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described large corpus of methods for multivariate meta-
analysis [33,36,37,62,101-103]. We proposed summary-
data based methods as well as methods for IPD.
Although the former are very easily implemented, the lat-
ter provide some very useful insights. By viewing the
meta-analysis data as a 2 × r × k contingency table [45]
allowed developing methods based on logistic regression,
multinomial logistic regression and Poisson regression.
Although logistic regression methods have long being
used for meta-analysis of IPD [33,36,37], multinomial
logistic regression has only being used for meta-analysis
of genetic association studies under the retrospective
likelihood [12,80]. Most importantly, Poisson regression
models have been used in entirely different contexts,
such as survival analysis [104] and meta-analysis of fol-
low-up studies with varying duration [105]. Thus, an
important advancement of this work is the extension of
the commonly used approach for analyzing haplotype
data [43,44] in the meta-analysis setting, describing
appropriately specified models and presenting them in a
unified framework (i.e. the contingency table analysis).
The empirical evaluation of the published literature sug-
gests that studies reporting meta-analysis of haplotypes
did not systematically differ from the meta-analyses of
genetic association using SNPs in terms of the average
sample size, but contain approximately half of the included
studies and produce significant results twice more often.
The meta-analyses that reported the complete data did
not significantly differ from the remaining studies in terms
of the included studies, the number of SNPs included in
the haplotypes, the proportion of significant findings or
the proportion of collaborative analyses. There was how-
ever, moderate evidence that the total sample size included
in the meta-analyses that reported complete data, was
smaller compared to the meta-analyses that did not.
The application of the methods proposed in this work in
studies that reported the complete data, made clear that
approximately half of the significant findings are attributa-
ble to the method of analysis used by the primary authors
and suffer from an inflated type I error rate. Indeed, for
the four out of the nine studies that reported significant
results, these were clearly refuted by the multivariate
methodology. Three of these studies used the 1 vs. other
approach, which although more powerful, is known to suf-
fer from increased type I error rate [61], whereas the
results of the fourth study were based on a misspecified
log-linear model. Two additional studies produced mar-
ginally insignificant results (i.e. the multivariate Wald test
contradicted the univariate one), mainly due to the exis-
tence of rare haplotypes or heterogeneity that has not
been accounted for in the initial analysis.
All the models presented here assume that the haplo-
types are directly observed. However, as we have already
discussed, the haplotypes are usually inferred and thus,
treating them as known quantities may be problematic
[30]. The general framework presented in this work can
be easily extended in order to account for this uncer-
tainty, simply by weighting the inferred haplotypes by
their probability [49,50]. However, this will probably be
problematic in many real life applications, except when
dealing with a collaborative analysis, since a meta-
analyst will rarely have access to individual genotype
data in order to use them to estimate the haplotypes
and their posterior probabilities. If combined genotypes
are available for all studies, the meta-analyst may try to
re-construct the haplotypes with a method of his/her
choice and perform the analysis using the posterior
probabilities as weights. Moreover, if individual genotype
data is available (from the literature or in a collaborative
setting), the framework can be extended to allow the
haplotype risk to follow models of inheritance other
than the multiplicative one (i.e. estimating the risk of
haplogenotypes), or to include patient-level covariates.
The methods proposed in this work, clearly outperform
the traditional naïve method of meta-analysis of haplo-
types, which simply consists of contrasting each haplotype
against the remaining ones. This is expected to be more
profound, especially as the number of possible haplotypes
increases, increasing also the type I error rate due to mul-
tiple comparisons [59,60]. Collapsing the haplotypes and
performing a univariate analysis, may potentially be more
powerful in several situations [61]. However, in genetic
association studies, even though we are interested in small
genetic effects we are also concerned about the probability
of false findings [106,107]. Thus, the multivariate metho-
dology seems to be a reliable alternative.
Conclusions
We presented multivariate methods that use summary-
based data as well as methods that use binary and count
data in a generalized linear mixed model framework
(logistic regression, multinomial regression and Poisson
regression). The methods presented here are easily
implemented using standard software such as Stata, R or
SAS making them easy to be applied even by non-
experts. In the Additional file 1, Stata code for fitting the
models described in this work is given and we expect
that these methods will be widely used in the future.
Additional material
Additional file 1: Stata code for fitting the methods described in
the manuscript. The commands should be run within a Stata do-file.
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